Multivariate Cox model for disease-free survival
| Characteristic . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR* . | P . | RR* . | P . | |
| Global series | ||||
| p21 Hypermethylation | 4.1 | < .001 | 3.4 | .0001 |
| WBC above 50 000 mm3 | 3.1 | .006 | — | — |
| BCR-ABL positivity | 2.9 | .005 | — | — |
| T phenotype | 2.2 | .03 | — | — |
| Age older than 15 years | 1.8 | .03 | — | — |
| Childhood ALL | ||||
| p21 Hypermethylation | 4.0 | .007 | 3.1 | .01 |
| T phenotype | 2.5 | .04 | — | — |
| WBC above 50 000 mm3 | 2.2 | .05 | — | — |
| NCI poor risk | 2.2 | .05 | — | — |
| PETHEMA poor risk | 1.8 | .05 | — | — |
| Adult ALL | ||||
| WBC above 50 000 mm3 | 4.9 | .002 | 4.1 | .003 |
| p21 Hypermethylation | 3.2 | .003 | 3.0 | .01 |
| BCR-ABL positivity | 2.3 | .006 | — | — |
| Characteristic . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR* . | P . | RR* . | P . | |
| Global series | ||||
| p21 Hypermethylation | 4.1 | < .001 | 3.4 | .0001 |
| WBC above 50 000 mm3 | 3.1 | .006 | — | — |
| BCR-ABL positivity | 2.9 | .005 | — | — |
| T phenotype | 2.2 | .03 | — | — |
| Age older than 15 years | 1.8 | .03 | — | — |
| Childhood ALL | ||||
| p21 Hypermethylation | 4.0 | .007 | 3.1 | .01 |
| T phenotype | 2.5 | .04 | — | — |
| WBC above 50 000 mm3 | 2.2 | .05 | — | — |
| NCI poor risk | 2.2 | .05 | — | — |
| PETHEMA poor risk | 1.8 | .05 | — | — |
| Adult ALL | ||||
| WBC above 50 000 mm3 | 4.9 | .002 | 4.1 | .003 |
| p21 Hypermethylation | 3.2 | .003 | 3.0 | .01 |
| BCR-ABL positivity | 2.3 | .006 | — | — |
RR indicates relative risk; ALL, acute lymphoblastic leukemia. For other abbreviations, see Table 1.
Relative risk of treatment failure as compared with patients without the adverse feature. In multivariate analysis, relative risk was calculated after adjustment for other factors in the final model; risks are shown only for factors that achieved independent significance.